Partially Hydrolysed Whey-Based Infant Formula Improves Skin Barrier Function

Sébastien Holvoet1, Sophie Nutten1, Lénaïck Dupuis2

  • 1Department of Gastrointestinal Health, Nestlé Institute of Health Sciences, Nestlé Research, Société des Produits Nestlé S.A., Vers-chez-les-Blanc, 1000 Lausanne, Switzerland.

Nutrients
|September 28, 2021
PubMed

Insights

Partially hydrolysed whey-based infant formula (pHF-W) may improve infant skin barrier function. This study found pHF-W reduced transepidermal water loss and improved skin hydration markers in mice and human cells.

Area of Science:

  • Immunology
  • Dermatology
  • Nutrition Science

Background:

  • Atopic dermatitis (AD) risk in infants is linked to milk allergy and impaired skin barrier function.
  • Partially hydrolysed whey-based infant formulas (pHF-W) have demonstrated potential in reducing AD risk.
  • The specific impact of pHF-W on skin barrier integrity requires further investigation.

Purpose of the Study:

  • To investigate the efficacy of oral pHF-W supplementation in enhancing skin barrier function.
  • To assess the effects of pHF-W on transepidermal water loss (TEWL) and immune responses.
  • To explore the molecular mechanisms underlying pHF-W's impact on skin barrier genes.

Main Methods:

  • Neonatal mice were supplemented with pHF-W and exposed epicutaneously to Aspergillus fumigatus.
  • Transepidermal water loss (TEWL) and total and specific IgE antibody levels were measured.
  • Human primary keratinocytes were stimulated in vitro to analyze skin barrier gene expression, including Aquaporin-3.

Main Results:

  • pHF-W supplementation significantly reduced TEWL and total IgE in mice.
  • Whey hydrolysate alone was sufficient to decrease TEWL and total IgE.
  • Aquaporin-3 gene expression, crucial for skin hydration, was modulated by pHF-W in both mice and human keratinocytes.

Conclusions:

  • Oral pHF-W supplementation may improve skin barrier function by reducing TEWL and modulating hydration-related genes.
  • Enhanced skin barrier function represents a potential mechanism through which pHF-W could lower AD risk in infants.
  • Further clinical trials in humans are necessary to validate these findings and confirm the efficacy of pHF-W for AD prevention.

Related Concept Videos

Surface Membrane Barriers01:18

Surface Membrane Barriers

The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.7K
Anatomy of the Intestines01:23

Anatomy of the Intestines

Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
84.2K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
31